ABCG2 and cancer: BCRP, categorized as an ABC half-transporter, is notably overexpressed in cancer cell lines treated with topotecan or mitoxantrone (MXT), leading to resistance against camptothecin (CPT) derivatives like irinotecan and SN-38 [133,134].